-

11:55:29 AM

PLX Stock News

PLX - Protalix BioTherapeutics Inc.

06/08/23 6:50 AM

AMEX, NYSE : PLX

conferences

Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell– based protein expression system, today...

RHEA-AI

neutral

05/30/23 6:50 AM

AMEX, NYSE : PLX

Protalix BioTherapeutics Issues Letter to Stockholders

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today announced the following letter from its President and Chief...

RHEA-AI

neutral

05/23/23 6:50 AM

AMEX, NYSE : PLX

Protalix BioTherapeutics set to join Russell 3000® Index

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell– based protein expression system, today announced that it is set to join the broad-market Russell 3000...

RHEA-AI

neutral

05/18/23 6:50 AM

AMEX, NYSE : PLX

Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases

On July 23, 2018, the Company's wholly-owned subsidiary entered into an Exclusive License and Supply Agreement with Chiesi Farmaceutici S.p.A., or Chiesi, pursuant to which the Company granted Chiesi an exclusive license to commercialize pegunigalsidase alfa in the United States. This followed the Exclusive License and Supply Agreement entered into...

RHEA-AI

neutral

05/10/23 6:00 AM

AMEX, NYSE : PLX

fda approval

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc., a biopharmaceutical company...

RHEA-AI

neutral

05/05/23 6:46 AM

AMEX, NYSE : PLX

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc., a biopharmaceutical...

RHEA-AI

neutral

05/04/23 6:50 AM

AMEX, NYSE : PLX

earnings

Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system,...

RHEA-AI

neutral

04/27/23 6:50 AM

AMEX : PLX

Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system,...

RHEA-AI

neutral

03/21/23 6:50 AM

AMEX : PLX

clinical trial

Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout

The study is being conducted at New Zealand Clinical Research under the New Zealand Medicines and Medical Devices Safety Authority and the Health and Disability Ethics Committee guidelines, and is expected to enroll approximately 56 patients with no previous exposure to PEGylated uricase. "We are pleased to initiate this first in human trial of PRX-115,"...

RHEA-AI

neutral

03/13/23 6:50 AM

AMEX : PLX

Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx ®. Protalix was the first company to gain U.S. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

PLX Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.protalix.com
CeoDror Bashan
Security nameProtalix BioTherapeutics Inc.
Issue typecs
SectorManufacturing
Sic code2836
Employees197
Tags
- Health Services
- Services to the Health Industry
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
StateKarmiel
City2 Snunit St Science Park Pob 455
Zip2161401
CountryIsrael
Phone97249028100

About Protalix BioTherapeutics Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human α–Galactosidase–A protein for the proposed treatment of Fabry disease; OPRX–106, an orally–delivered anti-inflammatory treatment; alidornase alfa or PRX-110, for the treatment of various human respiratory diseases or conditions; PRX–115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa, and with SarcoMed USA, Inc. for the worldwide development and commercialization of PRX–110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery.